Optinose announced the peer-review publication of a paper titled, “EDS-FLU efficacy in patients with chronic rhinosinusitis with or without prior sinus surgery in ReOpen1 and ReOpen2 randomized controlled trials”1 in the International Forum of Allergy & Rhinology, the journal of the American Rhinologic Society. In these trials, XHANCE improved symptoms, sinus opacification, and quality of life in both groups of CRS patients either with or without prior sinus surgery, indicating that previous surgery is not required for patients with CRS to experience the benefits of treatment with XHANCE and that XHANCE can be helpful for patients even after surgery.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OPTN:
- New Peer-Reviewed Data Highlight the Benefits of XHANCE in Chronic Rhinosinusitis Patients with or without Prior Sinus Surgery
- Optinose to Present at the H.C. Wainwright 26th Annual Global Investment Conference
- Optinose sees FY24 XHANCE net revenue $85M-$90M
- Optinose reports Q2 EPS (7c), consensus (8c)
- Optinose Announces Reporting Date for Second Quarter 2024 Financial Results